T he electrophysiological remodeling that occurs during cardiac pathologies, such as hypertrophy, contributes to myocardial remodeling and plays an important role in the development of arrhythmia, increasing the risk of morbidity and mortality. 1 Reappearance of the T-type Ca 2ϩ current (I CaT ) has been observed in hypertrophied ventricular cells, in association with pressure overload, postinfarction, and cardiomyopathy. [2] [3] [4] Little is known about the pathophysiological role of I CaT , but its activation at low voltage suggests that I CaT may be related to Ca 2ϩ overload and arrhythmias. 4 The relationship between I CaT and cardiac damage is highlighted by the therapeutic benefits of blocking I CaT . 5, 6 For example, the use of a selective I CaT antagonist, mibefradil, has been shown to improve survival in a rat model of chronic heart failure. 7 Previous studies showed that I CaT is developmentally regulated in rodent ventricular cells. 8, 9 In the fetus, I CaT is generated by both Ca V 3.1 (␣1G) and Ca V 3.2 (␣1H) poreforming channels whereas in newborn rat ventricles, only Ca V 3.1-related current can be recorded. Furthermore, I CaT is no more detectable in adult rat ventricles. The cardiac pattern of expression of T-type channels, together with previous reports describing the relationship between I CaT and cell proliferation, is consistent with Ca 2ϩ uptake through I CaT being dedicated to specific functions related to the cell cycle. 10 -12 I CaT density increases after growth hormone stimulation, 13 and thus I CaT may also be associated with growth processes in nonproliferating adult hypertrophied myocytes.
Few studies have been reported concerning the effectors/ mechanisms involved in regulation of the expression of cardiac T-type channels. 14 Among the factors stimulated during cardiac hypertrophy, it has been shown that acute application of endothelin (ET)-1 to cultured newborn rat ventricular cells increases I CaT density due to the activation of protein kinase C. 15 Conflicting results have been obtained concerning adrenergic stimulation, which has been reported to have no effect or to increase the density of I CaT in the ventricle. 16, 17 To our knowledge, the only study describing the effects of angiotensin II (Ang II) stimulation in cardiac tissue was performed in frog atrial cells and reported an increase in I CaT density in response to acute Ang II application. 18 In the heart, Ang II is known to play a critical role in ventricular hypertrophy and several aspects of signal transduction in response to Ang II stimulation resemble features of the signal transduction induced by growth factors. 19 Ang II exerts its hypertrophic effect by activating G-protein-coupled type 1 Ang II receptors (AT 1 ) and initiating a number of well-defined intracellular signaling pathways. 20 Considerable efforts are currently being made to identify the signaling molecules involved in hypertrophic responses, such as those involved in the mitogen-activated protein kinase (MAPK) cascade. 21 Recent data have demonstrated that a MAPK cascade component, the extracellular signal-regulated kinase 1/2 (ERK1/2) activated by the MAPK kinase-1/2 (MEK1/2), may be an important component connecting several signaling pathways involved in hypertrophy. 22 In this study, we demonstrate for the first time that Ca 2ϩ entry through I CaT is increased by the Ang II-activated AT 1 cascade in left ventricular hypertrophied myocytes. We also show that Ca V 3.1 and Ca V 3.2 subunits participated to the reexpressed I CaT and these subunits are differently regulated. Finally, Ang II-activated MEK pathway and ET-activated independent MEK pathway are shown to regulate the expression of I CaT -related subunits.
Materials and Methods

Hypertrophic Model
Animals were cared for and used in accordance with the European convention for the protection of vertebrate animals used for experimental purposes, and institutional guidelines n°86/609/CEE November 24, 1986 . Adult male Wistar rats (IFFA Credo, France) weighing 150 to 170 g were subjected to abdominal aortic stenosis during 6 or 12 weeks as previously described. 23 Stenosed rats (AS) were paired with sham-operated rats (CTL) of the same weight and age. Twelveweek rats were treated with losartan (AS/L) for 2 weeks (12 mg/kg per day) via Alzet miniosmotic pumps (model 2002) inserted into the intraperitoneal cavity. 24 Losartan was generously provided by MERCK.
Isolation of Adult Cardiomyocytes and Culture of Newborn Cardiomyocytes
Left ventricular myocytes were isolated enzymatically from adult rat hearts by retrograde perfusion, as described elsewhere. 25 Cultures of newborn myocytes were prepared from the ventricles of 1-to 2-day-old Wistar rats, as described by Renaud et al. 26 Twenty-four hours after plating, myocytes were incubated for 48 hours with Ang II (0.1 mol/L, Sigma) or Ang II plus antagonists/inhibitors in fetal calf serum-free medium supplemented with 10% heat-inactivated horse serum. 
Quantitative RT-PCR
Total RNA was prepared from ventricular tissues using Trizol (GIBCO-BRL). Reverse transcription (RT) and polymerase chain reaction (PCR) conditions, and the procedures used for quantification have been described elsewhere. 9 Briefly, quantitative RT-PCR was performed with normalized RNA aliquots (1 g) and a known amount of cRNA internal control (0.3ϫ10 6 molecules for both transcript species, for tissues, and 2.5ϫ10 6 molecules for cultures). The internal control differed from the target counterpart by only one restriction site. PCR was performed with a trace amount of 32 Plabeled 5Ј primer. The number of copies per g of total RNA was calculated using the following equation: [Internal control weight/ (size in nucleotidesϫ330)]ϫ6.02ϫ10 23 , and from the relationship [molecules cRNA control/cpm cRNA control]ϫcpm targetϭtarget molecules per normalized RNA aliquot.
Statistical Analysis
Data are expressed as meanϮSE. N and n correspond to the number of animals and the number of cells, respectively. Statistical significance was estimated by one-way ANOVA followed by Dunnett's test to identify differences between groups. Differences were considered significant if PϽ0.05.
Results
Ang II Is Involved in the Stenosis-Induced Increase in I CaT Density
We have used a model of stenosed rat treated with losartan to examine the putative effect of Ang II in the reexpression of I CaT . After 6 weeks of stenosis, although left ventricular cells were hypertrophied by 52% compared with control cells (234Ϯ6 pF, nϭ10 versus 154Ϯ29 pF, nϭ10; PϽ0.01), no I CaT was detected at this time. In long-term stenosis AS group (12 weeks), the cell membrane capacitance increased by 1.5-fold as in 6-week-stenosed group (Table 1) . Two weeks of losartan treatment decreased heart weight/body weight ratio without affecting cell size (AS/L versus AS). As it has BW indicates body weight; HW, heart weight; HW/BW, heart weight/body weight ratio; CTL, sham-operated; AS, abdominal aortic stenosis; AS/L, abdominal aortic stenosis plus losartan treatment; N, number of animals; and n, number of cells. *PϽ0.001 vs CTL; †PϽ0.01 vs AS.
been shown that losartan treatment prevents increase in the interstitial collagen fraction in rat heart after aortic stenosis, 24 the decrease in hypertrophy in AS/L rats was probably due to a decrease in interstitial fibrosis. (Figure 2A ). We have checked that in sham-operated losartan group, neither the procedure nor the 2 additional weeks have any effect on I CaT (0.41Ϯ0.04 pA/pF, nϭ9). We have also tested that I CaT density is insensitive to acute application of losartan (2 mol/L) in freshly isolated hypertrophied myocytes (0.44Ϯ0.06 pA/pF, nϭ6). Then the reduction of I CaT density in AS/L results from AT 1 blockade by losartan. As neither activation nor steady-state inactivation parameters of I CaT were modified after losartan treatment ( Figure 2B and Table  2 ), it can be postulated that the blockade of the AT 1 pathway induced the decrease in functional channel density, leading the decrease in I CaT density.
The impact of cardiac hypertrophy on L-type Ca 2ϩ current (I CaL ) density remains unclear as previous studies have reported either a decrease or an increase of I CaL density during pathology (see review 27 ). We found that neither stenosisinduced pressure overload nor losartan treatment altered I CaL density in hypertrophied myocytes (9.9Ϯ0.5 pA/pF, nϭ22, 10.9Ϯ1.0 pA/pF, nϭ26 and 10.0Ϯ0.7 pA/pF, nϭ27 for CTL, AS, and AS/L cells, respectively). The activation and steady-
TABLE 2. Activation and Inactivation Parameters of Cardiac Calcium Currents
Activation Inactivation
Half-Activation, mV Slope, mV Half-Inactivation, mV Slope, mV
Values are meanϮSE; n indicates number of cells; T, T-type Ca 2ϩ current; L, L-type Ca 2ϩ current; V 0.5 , potential of half-activation or half-inactivation; k, slope factor; CTL, sham-operated; AS, abdominal aortic stenosis; and AS/L, abdominal aortic stenosis plus losartan treatment. 
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state inactivation voltage relationships of I CaL were also unaffected ( Table 2 ).
Characteristics and Regulation of the Functional I CaT Pore-Forming ␣1 Subunits
We tested the Ni 2ϩ sensitivity of I CaT in order to determine the ␣1 subunit-related currents induced during cardiac hypertrophy ( Figure 3A) . The Ni 2ϩ dose-response relation indicated that I CaT was blocked in a biphasic manner with IC 50 of 1.6 and 240 mol/L. According to previous reports, 1.6 and 240 mol/L Ni 2ϩ sensitivity corresponds to sensitivity described for Ca V 3.2-and Ca V 3.1-related current, respectively. 28, 29 Also, the relative contribution of Ca V -related current in I CaT was assessed from Ni 2ϩ dose-response relation. We found that Ca V 3.1 and Ca V 3.2 contribute to 80% and 20%, respectively. Interestingly, because there was no difference between Ni 2ϩ dose-response curves in AS and AS/L, it appeared that the relative contributions of Ca V 3.1 and Ca V 3.2 subunits to I CaT were not modified by losartan treatment ( Figure 3A) . These data indicated that the decrease in I CaT density after AT 1 blockade was due to a proportional decrease in the density of functional Ca V 3.1 and Ca V 3.2 subunits. The Ang II signaling pathway then mediates upregulation of the expression of Ca V 3.1 and Ca V 3.2 subunits during stenosis-induced cardiac hypertrophy.
We investigated the regulation of Ca V 3.1 and Ca V 3.2 expression by quantifying transcript amount ( Figure 3B ). Neither aortic stenosis nor losartan treatment affected the amount of Ca V 3.2 mRNA (0.53Ϯ0.07, 0.52Ϯ0.06, and 0.51Ϯ0.10ϫ10
6 molecules per g of total RNA in CTL, AS and AS/L groups, respectively). As losartan treatment decreased the density of functional Ca V 3.2 subunits, Ang II probably regulated Ca V 3.2 channel expression at the posttranscriptional level. Conversely, the amount of Ca V 3.1 transcripts increased by almost 3-fold in hypertrophied group (0.70Ϯ0.04 versus 0.25Ϯ0.09ϫ10 6 molecules in AS versus CTL cells; PϽ0.001), and this increase was abolished by losartan treatment (0.29Ϯ0.03ϫ10 6 molecules). Therefore, during stenosis-induced hypertrophy, regulation of the amount of Ca V 3.1 mRNA is entirely dependent on Ang II signaling pathway.
Ang II Stimulates I CaT Channel Expression in Cultured Newborn Cells via the MEK1/2 Pathway
We investigated the Ang II intracellular signaling events involved in the expression of the T-type channels in ex vivo model. Previous experiments have indicated that chronic Ang II stimulation failed to reexpress I CaT in cultured adult ventricular cells (data not shown). Therefore, we have investigated the effect of Ang II in newborn ventricular cells that are known to exhibit basal I CaT .
Cultured newborn cells exhibited a typical I CaT , the density of which was increased under Ang II stimulation (8.1Ϯ0.8 pA/pF, nϭ10, for Ang II and 3.6Ϯ0.3 pA/pF, nϭ8, for CTL; PϽ0.001) (Figures 4A and 4B) . Treatment of myocytes with losartan had no effect on basal I CaT density (3.5Ϯ0.8 pA/pF, nϭ8) and completely blocked the Ang II-induced increase of I CaT density (3.8Ϯ0.4 pA/pF, nϭ10; PϽ0.001) ( Figure 4B ). Because an AT 2 receptor antagonist, PD123319, had no effect on Ang II-induced increase of I CaT density (6.8Ϯ0.9 pA/pF, nϭ5), then Ang II upregulates I CaT density via AT 1 receptor.
The increase in I CaT density was not associated with changes in the activation and steady-state inactivation parameters ( Figure 4C) . Thus, the Ang II-induced increase in I CaT density resulted from an increase in functional channel density in vitro. Interestingly, as in untreated cells, Ni II-stimulated cells exhibited Ca V 3.1-related current but are not potent to reexpressed functional Ca V 3.2 subunits.
We investigated whether ERK1/2 activation plays a role in the Ang II-induced increase in I CaT density using MEK1/2 inhibitors (UO126 and PD98059). Peak I CaT density with UO126 (5.0Ϯ0.2 pA/pF, nϭ6) did not differ significantly from that with PD98059 (5.2Ϯ0.5 pA/pF, nϭ6), and both reduced the Ang II-induced I CaT density by 65% ( Figures 5A and 5B). The reduction of I CaT density was due to the inhibition of Ang II effect because I CaT was not significantly different in cultures treated with UO126 alone or untreated (3.0Ϯ0.7 pA/pF, nϭ6) ( Figure 5B ). Because no change in the activation and steady-state inactivation characteristics of I CaT was observed after MEK1/2 inhibition, we can propose that the regulation of functional Ca V 3.1 channel density is mediated by Ang II-activated MEK1/2-dependent pathway. Use of a higher concentration of MEK1/2 inhibitor (75 mol/L) did not further inhibit the Ang II-induced increase in I CaT density (5.5Ϯ0.5 pA/pF, nϭ5). Then the remaining I CaT density is related to an Ang II-activated MEK1/2-independent pathway.
We found that the Ang II-activated signaling pathway increased the number of Ca V 3.1 transcripts (1.93Ϯ0.02 and 3.16Ϯ0.16ϫ10 6 molecules per g of total RNA in untreated and Ang II-treated cells, respectively; PϽ0.001) ( Figure 5C ). The increase in Ca V 3.1 mRNA amount was partially prevented by applying PD98059 or UO126 (2.53Ϯ0.08 and 2.36Ϯ0.07ϫ10 6 molecules, respectively, nϭ3; PϽ0.05). Although our data clearly reveal the implication of an activated MEK1/2-dependent pathway in the regulation of Ca V 3.1 transcript amount, an additional Ang II-activated pathway also seems to be involved in this process.
Autocrine Effect of ET on I CaT Channel Expression After Ang II Stimulation in Cultured Newborn Cells
It has been reported that in cultured cardiomyocytes, Ang II increases the synthesis of ET-1, which may act as an autocrine/paracrine factor. 30 We tested the putative autocrine effect of ET on the expression of T-type channels using multiple ET receptor antagonists: a dual ETA and ETB (bosentan), specific ETA (BQ123), and specific ETB (BQ788) (Figure 6 ). We found that the Ang II-induced I CaT density was significantly reduced by bosentan (5.4Ϯ0.3 pA/pF, nϭ11; PϽ0.05) and BQ123 (4.8Ϯ0.4 pA/pF, nϭ6; PϽ0.05), whereas BQ788 had no effect (8.2Ϯ0.8 pA/pF, nϭ8). To rule out the possibility that bosentan decreased basal I CaT density instead of the Ang II-increased I CaT density, we verified that I CaT density remained stable in cells treated by bosentan alone (3.9Ϯ0.3 pA/pF, nϭ5). These results showed that ETA stimulation mediated an autocrine ET response that participated to upregulation of I CaT . In accordance to that, 48 hour application of ET (0.1mol/L) increased I CaT density (5.4Ϯ0.8 pA/pF, nϭ7 versus 3.6Ϯ0.3 pA/pF, nϭ8 for CTL; PϽ0.05) and this increase was abolished by BQ123 (3.2Ϯ0.3 pA/pF, nϭ6).
The increase in I CaT density observed in cultured ventricular cells stimulated with Ang II reflects an additive effect of the Ang II-and ET-activated signaling pathways. Because cotreatment with bosentan and UO126 abolished the Ang II-induced in- 
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crease in I CaT density (3.0Ϯ0.6 pA/pF, nϭ6) ( Figure 6 ), we can postulate that a MEK1/2 independent ET-signaling pathway is involved in the regulation of Ca V 3.1. The quantification of the amount of Ca V 3.1 mRNA indicated that bosentan treatment did not alter the Ang II-induced increase of Ca V 3.1 mRNA (3.13Ϯ0.06 versus 3.16Ϯ0.16ϫ10 6 molecules per g of total RNA, respectively). As expected, in culture newborn myocytes, chronic ET-1 application had no effect on basal Ca V 3.1 mRNA amount (1.9ϫ10 6 molecules). Therefore, we can conclude that MEK1/2 independent ET-signaling pathway is involved in the translational/posttranslational regulation of Ca V 3.1 subunit.
Discussion
This study provides data on the regulation of molecular and functional expression of T-type channels by Ang II in hypertrophied myocytes. We demonstrate that (1) Ang II via AT 1 increased Ca V 3.1-and Ca V 3.2-related current density in stenosis hypertrophied myocytes, (2) Ca V 3.1 and Ca V 3.2 were differently regulated because Ang II via AT 1 increased the amount of Ca V 3.1 mRNA but not those of Ca V 3.2, (3) in cultured newborn ventricular myocytes Ang II via AT 1 increased I CaT density and the amount of Ca V 3.1 mRNA through MEK1/2 pathway, and (4) increased I CaT density also resulted of the autocrine action of ET released by Ang II.
Long-term aortic stenosis displayed expression of an I CaT with kinetic properties and Ca V 3.1 and Ca V 3.2 pore-forming units related to those described for fetal ventricular I CaT . 9 However, compared with fetal I CaT , kinetic characteristics of I CaT in hypertrophied myocytes revealed a hyperpolarized shift in the voltage-dependent activation (Ϫ39.5Ϯ0.8 mV, nϭ7, versus Ϫ22.4Ϯ0.6 mV, nϭ9, for AS and 18-day-old fetal ventricular cells, respectively), 9 and this hyperpolarized shift was insensitive to Ang II. Because Ca 2ϩ calmodulindependent protein kinase II (CaMKII) shifts the activation of I CaT to more negative potentials in adrenal glomerulosa cells, 31 and that CaMKII is upregulated in hypertrophied ventricles from rats, 32 then CaMKII might be responsible for the hyperpolarized shift in I CaT activation in AS cells.
Interestingly, after 6 weeks of stenosis, although left ventricular cells were hypertrophied, no I CaT was yet reexpressed. We can note that between 6 and 12 weeks, cell membrane capacitance increased in the same way in AS than in control indicating that hypertrophy was compensated. Therefore, whereas a hypertrophic background is necessary to reexpress I CaT , long-term compensate phase of hypertrophy is required for efficient expression of T-type channels, which is likely due to the activation of a time-dependent regulator factor. Supporting that, we have observed that Ang II stimulation was inefficient to reexpress I CaT in cultured adult ventricular myocytes. Therefore, further ex vivo investigation of the regulation of I CaT had required myocytes potent to express I CaT such as newborn myocytes.
Ang II increased the expression of T-type channel subunits via AT 1 -stimulated signaling pathway. Ni 2ϩ sensitivity revealed that functional Ca V 3.1 and Ca V 3.2 channels participate to Ang II-induced increase in I CaT density in stenosed rats. The amount of Ca V 3.2 mRNA remaining stable during stenosis-induced hypertrophy indicates that no hypertrophyassociated factor appears efficient to increase neither Ca V 3.2 promoter activity nor mRNA stability. It appears that the stenosis-induced increase in functional Ca V 3.2 proceeds through translational and/or posttranslational regulation. In newborn myocytes, Ca V 3.2 is also mainly regulated by translational and/or posttranslational mechanism because there is no more functional subunit while mRNA regulation persists. 9 The blockade of functional Ca V 3.2 subunit is maintained in cultured newborn myocyte even after Ang II treatment. Therefore, we can propose that Ang II in addition to an unidentified stenosis-induced factor is crucial to ensure the increase of functional Ca V 3.2 subunit.
In contrast to Ca V 3.2 regulation, the amount of Ca V 3.1 mRNA increased during stenosis-induced hypertrophy and this increase entirely depends on the activation of AT 1 signaling pathway. As a residual Ca V 3.1 related current persisted after AT 1 blockade, we can assure that in addition to the transcriptional regulation, Ca V 3.1 expression is regulated through translational and/or posttranslational mechanisms.
The stenosis-associated changes in I CaT density and Ca V 3.1 mRNA amount can be reproduced by application of Ang II to newborn rat myocytes and thereafter blocked by losartan. Thus, Ang II-treated cultures of myocytes appear to be one relevant model for investigating the AT 1 signaling pathways involved in the regulation of Ca V 3.1 expression. We show in this study that Ang II treatment leads to an increase in the amount of Ca V 3.1 mRNA, partly through ERK1/2-dependent activation. These data are consistent with a large body of study implicating the MAPK cascade in hypertrophic responses. 19 It should be noted that ERK1/2 is activated by stenosis-induced cardiac pressure overload 33 and that the MEK/ERK pathways have been shown to be involved in the reexpression of fetal genes in hypertrophic background. 34 It seems reasonable to postulate that the stenosis-induced regulation of the amount of Ca V 3.1 mRNA is mediated by Ang II activated MEK/ERK pathway. Further studies are required to evaluate the role of Ang II-activated ERK1/2 in the regulation of T-type channel expression in pathological situations.
It was previously shown that some of the cardiovascular hypertrophic effects of Ang II result from the autocrine/ paracrine release of ET. 30, 35 Consistent with this, we demonstrated that the effect of Ang II stimulation on I CaT density is decreased by ETA receptor blockade in cultured myocytes. Both ET-1 and Ang II activate similar G-protein-coupled receptor signaling pathways, including those activating ERK1/2. 36 Another important finding is that the blockade of ET signaling pathways did not affect the transcriptional regulation of Ca V 3.1, neither in Ang II-induced ET autocrine effect nor in chronic application of ET. Therefore, ET signaling pathway regulates functional Ca V 3.1 protein density through a translational and/or posttranslational mechanism. Finally, coblockade of ERK1/2 and ETA decrease more strongly I CaT density than ERK1/2 blockade alone suggesting that ET regulates Ca V 3.1 through an independent MEK/ERK pathway. This indicates that Ang II and ET use different signaling mechanisms for I CaT expression in cultured myocytes.
It is not surprising that several hypertrophic factors regulated T-type channels because the blockade of Ang II effect did no wholly abolished I CaT in stenosed rats. As no more transcriptional upregulation of channel subunits occurs after losartan treatment, the residual I CaT likely results from translational and/or posttranslational mechanism. Cultured newborn cell data lead us to propose that this latter mechanism can be ensured by ET signaling pathways activation.
This study provides new evidence that Ang II is closely related to electrophysiological remodeling process that occurs during cardiac hypertrophy. In addition to I CaT , another inward current, I f , has been shown to be upregulated by Ang II during cardiac hypertrophy. 37, 38 As I CaT and I f are both considered to ensure pacemaker activity, 39, 40 alterations in I CaT and I f density likely contribute to the increased propensity of the hypertrophied heart to develop arrhythmia. 27 In addition to its involvement in abnormal electrical properties, I CaT has been shown to contribute to Ca 2ϩ -dependent hormone secretion. 41, 42 It would therefore seems to be important to consider the biological role of I CaT with respect to pathogenesis of Ca 2ϩ overload effects 4 such as the activation of Ca 2ϩ -dependent transduction pathways required after longterm compensate cardiac hypertrophy.
In conclusion, we found that Ang II through AT 1 -activated MEK-dependent pathway is responsible for the regulation of Ca V 3.1 transcription (promoter activity and/or mRNA stability), whereas ET through ETA-activated MEK-independent pathway is implicated in Ca V 3.1 posttranscriptional regulation (translational and/or posttranslational mechanism). Unfortunately, Ca V 3.2 is not expressed in cultured myocytes that avoid detailed description of mechanisms involved in its regulation. However, we show that Ca V 3.2 is only regulated at posttranscriptional level and this regulation is also mediated by Ang II. Altogether these regulations of the channel subunits lead to I CaT expression that contributes to cardiac electrophysiological remodeling. Future studies will be needed to precisely explain the relationship between I CaT expression and pathophysiological events.
